Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avelumab Phase 3 Trial (Japan, jRCT2080223423)
jRCT2080223423Phase 3Terminated
- Start
- Dec 2016
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3 trial of avelumab. Started Dec 2016; status: terminated.
02
Drugs
avelumab
Beyond the preview
Go deeper on jRCT2080223423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223423.